螺内酯防治实验性大鼠肝纤维化作用研究  

Effects of spironolactone on hepatic fibrosis in rats

作　　者：苌新明[1] 张盈涛[1] 贾皑[1] 常英[1] 厉英超[1] 

机构地区：[1]西安交通大学第一医院消化科,陕西西安710061

出　　处：《临床肝胆病杂志》2003年第5期315-316,共2页Journal of Clinical Hepatology

摘　　要：探讨螺内酯对肝纤维化的防治作用。雄性SD大鼠46只,随机分成对照组(6只);模型组(30只),复合因素制成肝纤维化模型;螺内酯预防组(10只),造模方法同模型组,螺内酯每天100mg·11ml灌胃。于第8W末,将模型组(16只)再随机分为A组(肝硬化组)8只,用等量自来水灌胃;B组(螺内酯治疗组)8只,螺内酯灌胃8w。分别观察肝内纤维组织变化。显示螺内酯预防组肝脏I、Ⅲ型胶原、纤维连接蛋白、层粘蛋白增生明显减低(P<O.01),星状细胞数目减少。螺内酯治疗组肝纤维化程度无明显改变(P>O.05)。To study the preventive and therapeutic effects of spironolactone on hepatic fibrosis in rats. 46 male SD rats were randomly divided into three groups. Control group (6 rats); Model group (30 rats) and spironolactone prevention group (10 rats) whose liver fibrosis were induced by compound agents; spironolactone was given 100mg/kg per day by injecting into stomach to prevention group. At the end of 8th week, the model group was randomly divided into A group (liver cirrhosis group, 8 rats) was given water into stomach and B group (spironolactone therapeutic group, 8rats)was given spironolactone into stomach. Liver fibrosis was examined. The Ⅰ ,Ⅲcollagen, laminin, fibronectin were significantly decreased in spironolactone prevention group ( P < 0.01). The number of HSC was also decreased. The grade of hepatic fibrosis in spironolactone therapy has no significantly difference (P>0.05).

关 键 词：螺内酯 实验 大鼠 肝纤维化 肝硬化 利尿剂 

分 类 号：R575.2[医药卫生—消化系统] R983.1[医药卫生—内科学]